Pulmatrix, Inc.(NASDAQ : PULM)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.74%||176.97||0.7%||$1352.49m|
|BMY||Bristol-Myers Squibb Co.||0.36%||76.23||1.0%||$1197.90m|
|MRK||Merck & Co., Inc.||1.26%||93.25||0.7%||$1136.00m|
|LLY||Eli Lilly & Co.||4.49%||299.11||1.1%||$892.99m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||0.65%||141.96||0.0%||$458.27m|
|HZNP||Horizon Therapeutics Plc||1.13%||90.35||5.4%||$200.40m|
|NVO||Novo Nordisk A/S||3.49%||107.68||0.1%||$190.60m|
Pulmatrix, Inc. is a clinical stage biotechnology company engaged in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.